Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Autologous Tumor-cell Vaccination And Lymphokine-activated Tumor-infiltrating Lymphocytes (LAK-TIL).

P. Mallmann
Published 1993 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
This paper references
10.1126/SCIENCE.3489291
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.
S. Rosenberg (1986)
Phenotypic and functional characterization of recombinant interleukin 2 (rIL 2)-induced activated killer cells: analysis at the population and clonal levels.
S. Ferrini (1987)
In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.
I. Yron (1980)
Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer.
P. Sondel (1988)
10.1016/S0140-6736(88)92982-0
MYOCARDIAL INJURY AFTER INTERLEUKIN-2 THERAPY
S. Osanto (1988)
10.1097/00007890-196411000-00001
EVALUATION OF THE TRYPAN BLUE TECHNIQUE FOR DETERMINATION OF CELL VIABILITY
J. Tennant (1964)
Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
S. Ettinghausen (1986)
10.1016/0022-1759(86)90079-7
Separation of tumor-infiltrating lymphocytes from tumor cells in human solid tumors. A comparison between velocity sedimentation and discontinuous density gradients.
T. Whiteside (1986)
10.1200/JCO.1988.6.5.839
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.
S. Topalian (1988)
10.1002/EJI.1830180803
Modification of tumor cells by a low dose of Newcastle Disease Virus.
Paul Von Hoegen (1989)
10.1002/1097-0142(19850315)55:6<1236::AID-CNCR2820550616>3.0.CO;2-#
Prospectively randomized trial of adjuvant active‐specific immunotherapy for human colorectal cancer
H. C. Hoover (1985)
10.1002/IJC.2910110125
Immune responses in mice to tumour challenge after immunization with newcastle disease virus‐infected or X‐irradiated tumour cells or cell fractions
P. Beverley (1973)
10.1084/JEM.151.1.69
T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor
M. Berendt (1980)
10.1056/NEJM198704093161501
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
S. Rosenberg (1987)
10.1016/S0022-1759(87)80018-2
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials.
S. Topalian (1987)
10.1200/JCO.1989.7.1.1
Interleukin-2 therapy of human cancer: potential benefits versus toxicity.
R. Herberman (1989)
10.1111/j.1749-6632.1976.tb41717.x
IMMUNOTHERAPY OF OSTEOSARCOMA PATIENTS WITH VIRUS‐MODIFIED TUMOR CELLS *
A. Green (1976)
10.1056/NEJM198812223192527
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report.
S. Rosenberg (1988)
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.
M. Rosenstein (1986)
Vaccinia colon oncolysate immunotherapy for murine hepatic metastases can be modulated with low-dose interleukin-2. Third place winner: Conrad Jobst Award.
Y. Barnavon (1988)
Interleukin-2 in cancer therapy.
P. Dr (1988)
10.1002/1097-0142(19890101)63:1<102::AID-CNCR2820630117>3.0.CO;2-T
Functional and phenotypic analysis of tumor‐infiltrating. Lymphocytes isolated from human primary and metastatic. Liver tumors and cultured in recombinant interleukin‐2
S. Takagi (1989)
Phase I Clinical Trial of Interleukin 2 and α-Interferon: Toxicity and Immunologic Effects
G. Budd (1989)
10.1056/NEJM198704093161502
Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.
W. West (1987)
10.1002/IJC.2910320505
Expression of major histocompatibility antigens and nature of inflammatory cellular infiltrate in ovarian neoplasms
S. Kabawat (1983)
10.1002/IJC.2910370602
Separation, phenotyping and limiting dilution analysis of T‐lymphocytes infiltrating human solid tumors
T. Whiteside (1986)
Adoptive immunotherapy of a newly induced sarcoma: immunologic characteristics of effector cells.
S. Shu (1985)
10.1016/0090-8258(89)90182-0
Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report.
U. Beller (1989)
10.1056/NEJM198512053132327
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.
S. Rosenberg (1985)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar